Pomerantz Law Firm Announces Class Action against Hims & Hers Health, Inc. over Allegations of Securities Fraud

Investor Alert: Class Action Lawsuit Against Hims & Hers Health, Inc.

On July 17, 2025, Pomerantz LLP formally announced that a class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS), after allegations surfaced regarding potential securities fraud by the company and its leadership team. Investors who have experienced losses on their investments in Hims & Hers are encouraged to reach out to Pomerantz to understand better their legal rights and potential steps forward.

The class action lawsuit centers around whether Hims & Hers, along with certain officers and directors, engaged in unlawful business practices or securities fraud. Investors are advised that the deadline to request Court appointment as a Lead Plaintiff is August 25, 2025. Individuals interested in joining the movement can obtain a copy of the complaint online at Pomerantz’s official site, www.pomerantzlaw.com.

Recent Developments

The situation intensified on April 29, 2025, when Hims & Hers announced a significant collaboration with Novo Nordisk. This deal included the launch of a bundled offering of Novo Nordisk's FDA-approved drug, Wegovy®, through Hims & Hers’ platform. However, the tides shifted dramatically when, on June 23, Novo Nordisk terminated their partnership, citing alarming concerns over Hims & Hers' promotional integrity.

Novo Nordisk's press release stated that Hims & Hers allegedly engaged in deceptive practices, marketing what they described as 'illegitimate knock-off versions' of Wegovy® that posed threats to patient safety. The release pointed out that the company failed to comply with legal regulations regarding the sale of compounded drugs, misrepresenting them under claims of 'personalization.'

Crucially, investigations revealed that the active pharmaceutical ingredients in the purported knock-offs were sourced from non-FDA-approved foreign suppliers, raising significant alarm over safety standards. Following these revelations, Hims & Hers' stocks plummeted by 34.63%, dropping $22.24 to close at $41.98 per share. This decline emphasized the serious repercussions of the allegations against the company and the potential long-term implications for its investors.

Background on Pomerantz Law Firm

Founded by the late Abraham L. Pomerantz, Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class action litigation. The firm has built a legacy of serving the interests of shareholders and combating corporate misconduct. With a history spanning over 85 years, Pomerantz has secured numerous multimillion-dollar awards for victims of securities fraud. Their offices span key cities including New York, Chicago, Los Angeles, and internationally in London and Tel Aviv.

For those affected by Hims & Hers' recent struggles, this class action lawsuit presents a pathway to seek accountability and remedy. Investors still have time to take action; those interested should promptly contact Danielle Peyton at Pomerantz LLP for consultation and guidance on their next steps.

As time is of the essence, affected investors should not delay in reaching out to ensure they secure their place in this potential pursuit for justice. More information about the lawsuit and contact details for legal inquiries can be found at Pomerantz Law Firm’s website.